Incidence, Clinical Spectrum, Risk Factors and Impact of HIV-Associated Immune Reconstitution Inflammatory Syndrome in South Africa

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Haddow, Lewis John ^a,b   Moosa, Mahomed Yunus Suleman ^b   Mosam, Anisa ^b   Moodley, Pravi ^b,c   Parboosing, Raveen ^b,c   Easterbrook, Philippa Jane ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c INKOSI ALBERT LUTHULI CENTRAL HOSPITAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; HEMOGLOBIN;

ADULT; ADVERSE OUTCOME; ANTIVIRAL THERAPY; ARTICLE; CLINICAL FEATURE; CRYPTOCOCCOSIS; DISEASE ASSOCIATION; FEMALE; FOLLICULITIS; GENITAL ULCER; GEOGRAPHIC DISTRIBUTION; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPHADENOPATHY; MORBIDITY; MORTALITY; MUCOCUTANEOUS DISEASE; MUCOSAL DISEASE; PROTEIN BLOOD LEVEL; RISK FACTOR; SOUTH AFRICA; THORAX RADIOGRAPHY; TUBERCULOSIS; URBAN AREA; VERRUCA VULGARIS; VIRUS LOAD; WEIGHT REDUCTION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; MALE; RISK FACTORS; SOUTH AFRICA; VIRAL LOAD;

HERPES ZOSTER;

EID: 84869055060     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040623     Document Type: Article

References (67)

1. Murdoch DM, Venter WDF, Feldmann C, Van Rie A, (2008) Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 22: 601-610.
2. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ, (2006) Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clinical Infectious Diseases 42: 418-427.
3. French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, et al. (2000) Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Medicine 1: 107-115.
4. Espinosa E, Peña-Jiminez A, Ormsby CE, Vega-Barrientos R, Reyes-Teran G, (2009) Later onset of herpes zoster-associated immune reconstitution inflammatory syndrome. HIV Medicine 10: 454-457.
5. Huruy K, Mulu A, Mengistu G, Shewa-Amare A, Akalu A, et al. (2008) Immune reconstitution inflammatory syndrome among HIV/AIDS patients during highly active antiretroviral therapy in Addis Ababa, Ethiopia. Japan Journal of Infectious Diseases 61: 205-209.
6. Jevtović DJ, Salemovic D, Ranin J, Pesic I, Zerjav S, et al. (2005) The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Medicine 6: 140-143.
7. Müller M, Wandel S, Colebunders R, Attia S, Furrer H, et al. (2010) Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infectious Diseases 10: 251-261.
8. Letang E, Miró JM, Nhampossa T, Ayala E, Gascon J, et al. (2011) Incidence and predictors of immune reconstitution inflammatory syndrome in a rural area of Mozambique. PLoS One 6: e16946.
9. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, et al. (2008) Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. The Lancet Infectious Diseases 8: 516-523.
10. French MA, Price P, Stone SF, (2004) Immune restoration disease after antiretroviral therapy. AIDS 18: 1615-1627.
11. French MA, (2007) Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy. Current HIV/AIDS Reports 4: 16-21.
12. Narita M, Ashkin D, Hollender ES, Pitchenik AE, (1998) Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. American Journal of Respiratory and Critical Care Medicine 158: 157-161.
13. Navas E, Pilar M-D, Moreno L, Pintado V, Casado JL, et al. (2002) Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Archives of Internal Medicine 162: 97-99.
14. Kumarasamy N, Chaguturu S, Mayer KH, Solomon S, Yepthomi HT, et al. (2004) Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. Journal of Acquired Immune Deficiency Syndromes 37: 1574-1576.
15. Breton G, Duval X, Estellat C, Poaletti X, Bonnet D, et al. (2004) Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clinical Infectious Diseases 39: 1709-1712.
16. Lawn SD, Myer L, Bekker LG, Wood R, (2007) Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 21: 335-341.
17. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S, (2006) Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. Journal of Infection 53: 357-363.
18. Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, et al. (2005) Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antiviral Therapy 10: 417-422.
19. Haddow LJ, Colebunders R, Meintjes G, Lawn SD, Elliott JH, et al. (2010) Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infectious Diseases 10: 791-802.
20. Vidal JE, Penalva De Oliveira AC, Fink MCDS, Pannuti CS, Trujillo JR, (2008) AIDS-related progressive multifocal leukoencephalopathy: A retrospective study in a referral center in São Paulo, Brazil. Revista do Instituto de Medicina Tropical de Sao Paulo 50: 209-212.
21. Bower M, Nelson M, Young AM, Thirlwell C, Newsom-Davis T, et al. (2005) Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. Journal of Clinical Oncology 23: 5224-5228.
22. Letang E, Almeida JM, Miró JM, Ayala E, White IE, et al. (2010) Predictors of immune reconstitution inflammatory syndrome-associated with kaposi sarcoma in mozambique: a prospective study. Journal of Acquired Immune Deficiency Syndromes 53: 589-597.
23. Dunić I, Djurković-Djaković O, Vesić S, Zerjav S, Jevtović D, (2005) Herpes zoster as an immune restoration disease in AIDS patients during therapy including protease inhibitors. International Journal of STD and AIDS 16: 475-478.
24. Haddow LJ, Moosa MY, Easterbrook PJ, (2010) Validation of a published case definition for tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 24: 103-108.
25. Worodria W, Massinga-Loembe M, Mayanja-Kizza H, Namaganda J, Kambugu A, et al. (2011) Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART. Clinical and Developmental Immunology 2011: 758350.
26. Manabe YC, Campbell JD, Sydnor E, Moore RD, (2007) Immune reconstitution inflammatory syndrome. Risk factors and treatment implications. Journal of Acquired Immune Deficiency Syndromes 46: 456-462.
27. Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ, (2006) Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clinical Infectious Diseases 42: 1639-1646.
28. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, et al. (2005) Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19: 399-406.
29. Burman W, Weis S, Vernon A, Khan A, Benator D, et al. (2007) Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. International Journal of Tuberculosis and Lung Disease 11: 1282-1289.
30. Shelburne SA, Darcourt J, White WA, Greenberg SB, Hamill RJ, et al. (2005) The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clinical Infectious Diseases 40: 1049-1052.
31. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, et al. (2005) Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 19: 1043-1049.
32. Bicanic T, Meintjes G, Rebe K, Williams A, Loyse A, et al. (2009) Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. Journal of Acquired Immune Deficiency Syndromes 51: 130-134.
33. Valin N, Pacanowski J, Denoeud L, Lacombe K, Lalande V, et al. (2010) Risk factors for 'unmasking immune reconstitution inflammatory syndrome' presentation of tuberculosis following combination antiretroviral therapy initiation in HIV-infected patients. AIDS 24: 1519-1525.
34. National Antiretroviral Treatment Guidelines (2004). Pretoria: National Department of Health South Africa.
35. Haddow LJ, Easterbrook PJ, Mosam A, Khanyile NG, Parboosing R, et al. (2009) Defining immune reconstitution inflammatory syndrome: evaluation of expert opinion versus 2 case definitions in a South African cohort. Clinical Infectious Diseases 49: 1424-1432.
36. Mohammed A, Ehrlich R, Wood R, Cilliers F, Maartens G, (2004) Screening for tuberculosis in adults with advanced HIV infection prior to preventive therapy. International Journal of Tuberculosis and Lung Disease 8: 792-795.
37. Bouscarat F, Maubec E, Matheron S, Descamps V, (2000) Immune recovery inflammatory folliculitis. AIDS 14: 617-618.
38. Delfos NM, Collen AFS, Kroon FP, (2004) Demodex folliculitis: a skin manifestation of immnune reconstitution disease. AIDS 18: 701-708.
39. Rajendran PM, Dolev JC, Heaphy MR, Maurer T, (2005) Eosinophilic folliculitis before and after the introduction of antiretroviral therapy. Archives of Dermatology 141: 1227-1231.
40. Baalwa J, Mayanja-Kizza H, Kamya MR, John L, Kambugu A, et al. (2008) Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active anti-retroviral therapy in Uganda. African Health Sciences 8: 190-195.
41. Easterbrook PJ, (2008) HIV immune reconstitution syndrome in sub-Saharan Africa. AIDS 22: 643-645.
42. Lipman M, Breen R, (2006) Immune reconstitution inflammatory syndrome in HIV. Current Opinion in Infectious Diseases 19: 20-25.
43. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R, (2008) Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22: 1897-1908.
44. Fairall LR, Bachmann MO, Louwagie GMC, van Vuuren C, Chikobvu P, et al. (2008) Effectiveness of antiretroviral treatment in a South African program. Archives of Internal Medicine 168: 86-93.
45. Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, et al. (2008) Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clinical Infectious Diseases 47: 1479-1485.
46. Castelnuovo B, Manabe YC, Kiragga A, Kamya MR, Easterbrook PJ, et al. (2009) Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clinical Infectious Diseases 49: 965-972.
47. Keiser O, Anastos K, Schechter M, Balestre E, Myer L, et al. (2008) Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Tropical Medicine and International Health 13: 870-879.
48. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367: 1335-1342.
49. Etard JF, Ndiaye I, Thierry-Mieg M, Guèye NF, Guèye PM, et al. (2006) Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20: 1181-1189.
50. UNAIDS (2010) Global report: UNAIDS report on the global AIDS epidemic. Geneva, Switzerland: UNAIDS.
51. Sharma SK, Dhooria S, Barwad P, Kadhiravan T, Ranjan S, et al. (2010) A study of TB-associated immune reconstitution inflammatory syndrome using the consensus case-definition. Indian Journal of Medical Research 131: 804-808.
52. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, et al. (2011) Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. New England Journal of Medicine 365: 1471-1481.
53. Zolopa AR, Andersen J, Komarow L, Sanne I, Sanchez A, et al. (2009) Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicentre randomized strategy trial. PLoS One 4: e5575.
54. Havlir D, Kendall M, Ive P, Kumwenda J, Swindells S, et al. (2011) Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. New England Journal of Medicine 365: 1482-1491.
55. Makadzange AT, Ndhlovu CE, Takarinda K, Reid M, Kurangwa M, et al. (2010) Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clinical Infectious Diseases 50: 1532-1538.
56. Lawn SD, Bekker LG, Myer L, Orrell C, Wood R, (2005) Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 19: 2050-2052.
57. Kambugu A, Meya DB, Rhein J, O'Brien M, Janoff EN, et al. (2008) Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clinical Infectious Diseases 46: 1694-1701.
58. Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, et al. (2011) Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Medicine 8: e1000391.
59. WHO (2010) Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. Geneva, Switzerland: Department of HIV/AIDS, Stop TB Department, World Health Organization.
60. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, et al. (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377: 1495-1505.
61. Jarvis JN, Harrison T, Lawn SD, Meintjes G, Wood R, et al. (2011) Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy.
62. Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, et al. (2010) Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clinical Infectious Diseases 51: 448-455.
63. Micol R, Tajahmady A, Lortholary O, Balkan S, Quillet C, et al. (2010) Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia. PLoS One 5: e13856.
64. WHO (2011) Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Geneva, Switzerland.
65. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, et al. (2009) Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clinical Infectious Diseases 48: 856-862.
66. Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, et al. (2007) Asymptomatic serum cryptococcal antigenaemia and early mortality during antiretroviral therapy in rural Uganda. Tropical Medicine and International Health 12: 929-935.
67. Haddow LJ, Mahlakwane MS, Ramdial PK, Moosa MY, (2009) Histopathology of Strongyloides stercoralis hyperinfection during immune reconstitution in an HIV-infected patient. AIDS 23: 1609-1611.